Fouda, Abdelrahman Y. http://orcid.org/0000-0003-3042-9425
Xu, Zhimin
Suwanpradid, Jutamas
Rojas, Modesto
Shosha, Esraa
Lemtalsi, Tahira
Patel, Chintan
Xing, Ji
Zaidi, Syed A.
Zhi, Wenbo
Stansfield, Brain K.
Cheng, Paul Ning-Man
Narayanan, S. Priya
Caldwell, R. William
Caldwell, Ruth B. http://orcid.org/0000-0003-0168-0354
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (4 R00 EY029373-03, EY11766)
Center for Integrated Healthcare, U.S. Department of Veterans Affairs (BX001233)
U.S. Department of Health & Human Services | NIH | National Eye Institute
Article History
Received: 16 February 2022
Revised: 15 August 2022
Accepted: 17 August 2022
First Online: 29 August 2022
Competing interests
: AF, RBC, and RWC have a pending patent on the use of arginase 1 as a treatment for ischemic retinopathies. PN-MC is the chief executive officer of Bio-Cancer Treatment International Limited and holds stocks or shares in Bio-Cancer Treatment International Limited.
: All studies were approved by the Augusta University IACUC and IRB committees. Patients or guardians were consented before participation in the study.